Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.52 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.51 |
| ▸ | ITGAL | P20701 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649023 | 0.89 | NEK1 (0.55) | NR3C1NEK1NR3C2PGRMMP2 | |
| SCHEMBL4646281 | 0.88 | NR3C1 (0.49) | NR3C1NEK1NR3C2PGRKMT2A | |
| SCHEMBL4646273 | 0.86 | NR3C1 (0.50) | NR3C1NEK1NR3C2PGRKMT2A | |
| SCHEMBL4649348 | 0.85 | NEK1 (0.48) | NR3C1NEK1NR3C2PGR | |
| SCHEMBL4647445 | 0.85 | NEK1 (0.65) | NR3C1NEK1NR3C2PGRMMP2 | |
| SCHEMBL4646869 | 0.81 | NEK1 (0.47) | NR3C1NEK1ITGB2ICAM1ITGAL | |
| SCHEMBL7141920 | 0.81 | NEK1 (0.55) | NR3C1NEK1NR3C2PGRKMT2A | |
| SCHEMBL4647511 | 0.77 | NEK1 (0.52) | NR3C1NEK1NR3C2PGRKMT2A | |
| SCHEMBL3128254 | 0.77 | NR3C1 (0.74) | NR3C1NEK1NR3C2PGR | |
| SCHEMBL3127701 | 0.76 | NR3C1 (0.75) | NR3C1NEK1NR3C2PGRMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | claimed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | claimed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | claimed |
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1964834-A1 | Sulphonyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255117-A1 | SULFONYLTRYPTOPHANOLS | FSHR, NPY1R, GNRHR | NR3C1 932/4885NEK1 4534/4885ITGB2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.